Memorial Sloan Kettering Cancer Center
New York, New York, United States
Dr. Falchi earned his MD degree Cum Laude and a board certification in Medical Oncology Cum Laude at the University of Perugia, Italy. He subsequently completed a postdoctoral fellowship at MD Anderson Cancer Center in Houston, TX, medicine residency at Yale-New Haven Hospital in New Haven, CT, and Hematology/Oncology fellowship at Columbia University Irving Medical Center in New York, NY. He is board certified in Internal Medicine, Hematology and Medical Oncology & is currently an Assistant Attending in the Lymphoma Service and Cellular Therapy Service at Memorial Sloan-Kettering Cancer Center and an Assistant Professor of Medicine at Weill Cornell Medical College, both in New York, NY. Dr. Falchi’s areas of interest include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. His current research is focused on the use of immunotherapy for the treatment of patients with B-cell NHL through the conduct of clinical and translational studies. He is the lead investigator in multiple national and global immunotherapy trials for patients with B-cell NHL. He authored or co-authored over 60 articles published in peer-reviewed journals, including the Journal of Clinical Oncology, The Lancet Oncology, Blood, Annals of Oncology, and Clinical Cancer Research, as well as numerous abstracts and several book chapters.
T-Cell Engagers in Oncologic Indication
Monday, October 27, 2025
8:30 AM – 9:00 AM Central Time
Disclosure(s): AbbVie, Genentech, ADC therapeutics, Seagen, Ipsen, Johnson & Johnson: Advisor or Review Panel Member (Ongoing); Genmab, AbbVie, Roche, Kite: Travel Support (Ongoing); Roche, Genentech, Genmab, AbbVie, Innate Pharma, Beigene, Astrazeneca: Grant/Research Support (Ongoing); Roche, Genentech, Genmab, AbbVie, Sanofi, Evolveimmune, Astrazeneca, Merck: Consultant (Ongoing); Roche, Genmab, AbbVie, Kite: Honoraria (Ongoing)
